索引于
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method

Hyun Ho Song, Kwang Sik Choi, Chan-Wha Kim and Young Ee Kwon

The aim of this study was to develop and validate f or determination of piroxicam in human plasma by new rapid HPLC method and to compare the relative bioavailability of two branded formulations of piro xicam in healthy Korean volunteers. The analysis running time of piroxicam was just 2 minutes using C 18 column (100 x 4.6 mm, 5 μ m) with variable wavelength detector (at 355 nm). This HPLC method was validated by examining the precision and accuracy for inter- and intra-day analy- sis. A randomized, open-label, single dose, 2-perio d cross- over method was performed in 28 subjects. For analy sis of pharmacokinetic properties, the blood samples we re drawn at 0, 1, 2, 3, 4, 5, 6, 12, 24, 48, 96 and 16 8 hours after dosing. The standard curve was linear (R 2 = 0.9999) over the concentration range of 0.1 - 6 μ g/mL. The rela- tive standard deviation (R.S.D.) and accuracy were 0.2 - 6.1 % and 95.4 - 104.0 %. After single dose of piro xicam 20 mg, the plasma pharmacokinetic parameters, C max , T max , t 1/2 and AUC t were 2.15 ± 0.25 μ g/mL, 2.44 ± 1.15 h, 46.84 ± 8.73 h and 107.42 ± 27.25 μ g·h/mL in the test drug. No significant differences were found based o n analysis of variance, with mean values and 90% CIs of test/reference ratio for these parameters as follow s: C max was 0.9351-1.0377; AUC 0-168 was 0.9510-1.0752. The developed method was successfully applied to bioequivalence study of two branded piroxicam capsu les in 28 healthy Korean. The results of pharmacokineti cs showed two branded piroxicam 20 mg formulations wer e bioequivalent, based on the regulatory definition.